ArticleMolecular therapy oncolytics2014
Combinatorial treatment with oncolytic adenovirus and helper-dependent adenovirus augments adenoviral cancer gene therapy.
Article in Molecular therapy oncolytics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 27 citations in OpenAlex.
- Integrating oncolytic adenoviruses into combination cancer therapy: Mechanisms, advances and clinical outlook.Clinical and translational medicine · 2026Review
- CAR-T cell therapy and reconstructive oncologic surgery in peripheral solid tumors-A narrative review.Cell reports. Medicine · 2025Review
- An automated and high-throughput approach for enhanced precision of adenoviral titering.Molecular therapy. Methods & clinical development · 2025Article
- Transdermal delivery of PeptiCRAd cancer vaccine using microneedle patches.Bioactive materials · 2025Article
- IL-12 encoding oNDV synergizes with CAR-T cells in orthotopic models of non-small cell lung cancer.Molecular therapy. Oncology · 2024Article
- Additional expression of T-cell engager in clinically tested oncolytic adeno-immunotherapy redirects tumor-infiltrated, irrelevant T cells against cancer cells to enhance antitumor immunity.Journal for immunotherapy of cancer · 2024Article
- Mesenchymal stromal cells protect combined oncolytic and helper-dependent adenoviruses from humoral immunity.Molecular therapy. Methods & clinical development · 2024Article
- Tutorial: design, production and testing of oncolytic viruses for cancer immunotherapy.Nature protocols · 2024Review
- Review
- Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies.Science advances · 2023Article
- HydrAd: A Helper-Dependent Adenovirus Targeting Multiple Immune Pathways for Cancer Immunotherapy.Cancers · 2022Article
- Current development in adenoviral vectors for cancer immunotherapy.Molecular therapy oncolytics · 2021Review
- A review on the advances and challenges of immunotherapy for head and neck cancer.Cancer cell international · 2021Review
- Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Article
- Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies.Journal of hematology & oncology · 2021Review
- Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors.Communications biology · 2021Article
- Oncolytic Adenoviruses for Cancer Therapy.International journal of molecular sciences · 2021Review
- Cancer-derived EVs show tropism for tissues at early stage of neoplastic transformation.Nanotheranostics · 2021Article
- Check and Checkmate: Battling Cancer with Multiplex Immunotherapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2020Article
- Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors.Molecular therapy : the journal of the American Society of Gene Therapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
Oncolytic adenoviruses (Onc.Ads) produce significant antitumor effects but as single agents they rarely eliminate tumors. Investigators have therefore incorporated sequences into these vectors that encode immunomodulatory molecules to enhance antitumor immunity. Successful implementation of this strategy requires multiple tumor immune inhibitory mechanisms to be overcome, and insertion of the corresponding multiple functional genes reduces the titer and replication of Onc.Ads, compromising their direct ant-tumor effects. By contrast, helper-dependent (HD) Ads are devoid of viral coding sequences, allowing inclusion of multiple transgenes. HDAds, however, lack replicative capacity. Since HDAds encode the adenoviral packaging signal, we hypothesized that the coadministration of Onc.Ad with HDAd would allow to be amplified and packaged during replication of Onc.Ad in transduced cancer cells. This combination could provide immunostimulation without losing oncolytic activity. We now show that coinfection of Onc.Ad with HDAd subsequently replicates HDAd vector DNA in trans in human cancer cell lines in vitro and in vivo, amplifying the transgenes the HDAd encode. This combinatorial treatment significantly suppresses the tumor growth compared to treatment with a single agent in an immunocompetent mouse model. Hence, combinatorial treatment of Onc.Ad with HDAd should overcome the inherent limitations of each agent and provide a highly immunogenic oncolytic therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.